

ASX Release

**INVESTOR WEBCAST NOTIFICATION
EXCLUSIVE US-MARKET LICENSE AGREEMENT WITH AKILI
INTERACTIVE**

TALi Digital Ltd (ASX: TD1, “**TALi**” or “**the Company**”) will provide a live video webcast and Q&A discussion hosted by Managing Director, Mr Glenn Smith **today at 12.30pm AEST**.

The webinar will provide an overview of the Company and address TALi’s exclusive licensing deal with Akili Interactive Lab, Inc. (Akili), announced to the ASX yesterday. To participate in this webcast, please use the following link:

Direct Link: <https://zoom.us/j/92046686632?pwd=M1RpcVZvYTI1VCtKUDNRdU4xU29vZz09>

Release authorised by:

The Board of TALi Digital Limited

CONTACT

Corporate

Glenn Smith
TALi Digital Managing Director
1300 082 013
investors@talidigital.com

Investors

Bellevue Investor Relations
Katie Mackenzie
0455 502 197
kmackenzie@bellevueir.com.au

Catherine Ross
0421 997 481
catherine@irconsult.com.au

About TALi Digital

TALi [TALi Digital Limited (ASX: TD1)] is a digital health company delivering diagnostic and therapeutic solutions for cognitive function and behaviour. The Company has built a platform technology, the first iteration of which targets cognitive attention skills during early childhood through its evidence and video-gamed-based TALi screening (DETECT®) and training (TRAIN®). This first to market and user experience focused technology is complementary to existing diagnosis and therapy placing TALi at the forefront of patient experience and early intervention thus positioning the business as an ideal partner in the global digital health sector.

Innovations that target cognitive skills to deliver non-invasive early interventions underpin the TALi platform technology. This innovation focus is allowing the Company to deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder) for predictive diagnosis and treatment for all age groups along with a core research program exploring applications for at populations afflicted with Mild Cognitive Decline (MCI has been found to often been a precursor to recognizing Alzheimer’s disease and other forms of dementia). TALi solutions aim to deliver foundational advances in human cognitive function and behaviour only dreamt of a few short years ago.

At TALi, our vision is to create personalised **game** changing experiences to enhance cognitive function and behaviour from any digital device. Learn more at talihealth.com.au.